Table 2.
Comparison of COVID-19 anti-spike antibody titre and percentage of neutralizing antibody between the groups who were given two doses of vaccine at different intervals.
| Study Group | Anti-Spike Antibody Anti-Body Titre |
p Value | Neutralization Percentage | p Value | ||
|---|---|---|---|---|---|---|
| Group I: Interval ≤6 weeks | 2613 (310–7518) |
0.027 | 45.9 (15.4–92.0) |
<0.001 | ||
| Group II: Interval 7–12 weeks | 6365 (2968–9463) |
0.999 | 95.5 (57.6–98.0) |
0.386 | ||
| Group III: Interval 13–36 weeks | 5267 (1739–11,653) |
92.4 (73.8–97.5) | ||||
The titre of anti-spike antibody is expressed as U/mL and proportion of participants with neutralizing antibody is expressed as %. Quantitative data are expressed as median (interquartile range).